Skip to content
value.today

BioGenerics, Inc.

Total raised
$143 M
4 rounds on record
Latest round
$56 M
May 2014
First round on record
Jul 2011
Today
Went public
See the company page

BioGenerics, Inc. is listed today as Coherus Oncology, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BioGenerics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$7 MPrivate placement after listing$2 to $10 million

BioGenerics, Inc.: Private sale, Dec 2017

Investors in this round

1 investor had bought by the notice of Dec 13, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan C. Herman · Executive Officer
  • Barbara K. Finck, M.D. · Executive Officer
  • Dennis M. Lanfear · Executive Officer, Director
  • Jean Frederic J. Viret, Ph.D. · Executive Officer
  • Peter K. Watler, Ph.D. · Executive Officer
  • Ali J. Satvat · Director
  • August J. Troendle, M.D. · Director
  • Christos Bryan Richards · Director
  • James I. Healy, M.D., Ph.D. · Director
  • Mary T. Szela · Director
  • Mats J. Wahlstrom · Director
  • V. Bryan Lawlis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Dec 13, 2017. Read the notice at the SEC.

equitySEC
Sep 2015$10 MPrivate placement after listing$10 to $50 million

BioGenerics, Inc.: Private sale, Sep 2015

Investors in this round

1 investor had bought by the notice of Sep 17, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan C. Herman · Executive Officer
  • Barbara K Finck, M.D. · Executive Officer
  • Dennis M. Lanfear · Executive Officer, Director
  • Jean-Frederic J. Viret, Ph.D. · Executive Officer
  • Peter K. Watler, Ph.D. · Executive Officer
  • Ali J. Satvat · Director
  • August J. Troendle, M.D. · Director
  • Christos Bryan Richards · Director
  • James I. Healy, M.D., Ph.D. · Director
  • Mary T. Szela · Director
  • Mats J. Wahlstrom · Director
  • V. Bryan Lawlis, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Sep 17, 2015. Read the notice at the SEC.

equitySEC
May 2014$56 MNo. 4$50 to $250 million

BioGenerics, Inc.: Raise no. 4, May 2014

Investors in this round

35 investors had bought by the notice of Jun 4, 2014: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $66 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan C. Herman · Executive Officer
  • Barbara K. Finck, M.D. · Executive Officer
  • Dennis M. Lanfear · Executive Officer, Director
  • George G. Montgomery · Executive Officer
  • Ali J. Satvat · Director
  • August J. Troendle, M.D. · Director
  • Christos G. Richards · Director
  • J. Michael Lazarus, M.D. · Director
  • James I. Healy, M.D., Ph.D. · Director
  • Mats J. Wahlstrom · Director
  • S. Edward Torres · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jun 4, 2014. Read the notice at the SEC.

equitySEC
Jul 2013$28 MNo. 3$10 to $50 million

BioGenerics, Inc.: Raise no. 3, Jul 2013

Investors in this round

6 investors had bought by the notice of Jul 24, 2013: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $40 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. Lanfear · Executive Officer, Director
  • August J. Troendle, M.D. · Director
  • Christos Michael Richards · Director
  • Graham K. Crooke, M.D. · Director
  • John Michael Lazarus, M.D. · Director
  • Mats J. Wahlstrom · Director
  • S. Edward Torres · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 24, 2013. Read the notice at the SEC.

debt, optionsSEC
Jan 2012$46 MNo. 2$10 to $50 million

BioGenerics, Inc.: Raise no. 2, Jan 2012

Investors in this round

23 investors had bought by the notice of Jan 14, 2013: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $61 M offered; $15 M still to sell
Smallest investment taken
$1
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. Lanfear · Executive Officer, Director
  • August J. Troendle, M.D. · Director
  • Christos Michael Richards · Director
  • Graham K. Crooke, M.D. · Director
  • John Michael Lazarus, M.D. · Director
  • Mats J. Wahlstrom · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jan 14, 2013. Read the notice at the SEC.

equitySEC
Jul 2011$13 MNo. 1$10 to $50 million

BioGenerics, Inc.: Raise no. 1, Jul 2011

Investors in this round

15 investors had bought by the notice of Jan 3, 2012: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for BioGenerics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $14 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. Lanfear · Executive Officer, Director
  • August J. Troendle, M.D. · Director
  • Christos Michael Richards · Director
  • Graham K. Crooke, M.D. · Director
  • John Michael Lazarus, M.D. · Director
  • Mats J. Wahlstrom · Director
  • Stuart E. Builder, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Jan 3, 2012. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Coherus Oncology, Inc., its revenue in fiscal 2025 came from these product and service lines: Toripalimab $40.84 million (97%), Other revenue $1.34 million (3%).

    Annual report (SEC XBRL) · Dec 2025

  • BioGenerics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).

    SEC Form D · Dec 2017

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2017

Products and services#

No products or services of BioGenerics, Inc. are on record.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in BioGenerics, Inc.
InvestorKindAmountRoundRoleSource
Barbara K. FinckPersonnot statednot statedHeld Series B and C preferred stock (Form 3, 2014)SEC Form 3
Christos RichardsPersonnot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2014)SEC Form 3
Daiichi Sankyo Company, LTDCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Dennis M. LanfearPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3
James HealyPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3
KKR Biosimilar GP LLCOthernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Biosimilar L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR & Co. L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Fund Holdings GP LtdFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Fund Holdings L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Group Holdings L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Group LtdCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KKR Management LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lilly Eli & CoOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lilly Ventures Fund I LLCVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 35 investors.

Largest shareholders today

Institutions holding Coherus Oncology, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioGenerics, Inc.
NameRoleNamed in
Alan C. HermanExecutive officerDec 2017
Barbara K. Finck, M.D.Executive officerDec 2017
Dennis M. LanfearExecutive officerDec 2017
Jean Frederic J. Viret, Ph.D.Executive officerDec 2017
Peter K. Watler, Ph.D.Executive officerDec 2017
Barbara K Finck, M.D.Executive officerSep 2015
Jean-Frederic J. Viret, Ph.D.Executive officerSep 2015
George G. MontgomeryExecutive officerJun 2014
Ali J. SatvatDirectorDec 2017
August J. Troendle, M.D.DirectorDec 2017
Christos Bryan RichardsDirectorDec 2017
Dennis M. LanfearDirectorDec 2017
James I. Healy, M.D., Ph.D.DirectorDec 2017
Mary T. SzelaDirectorDec 2017
Mats J. WahlstromDirectorDec 2017
V. Bryan LawlisDirectorDec 2017
V. Bryan Lawlis, Ph.D.DirectorSep 2015
Christos G. RichardsDirectorJun 2014
J. Michael Lazarus, M.D.DirectorJun 2014
S. Edward TorresDirectorJun 2014
Christos Michael RichardsDirectorJul 2013
Graham K. Crooke, M.D.DirectorJul 2013
John Michael Lazarus, M.D.DirectorJul 2013
Stuart E. Builder, Ph.D.DirectorJan 2012

About

Company in Redwood City, United States.

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.